The estimated Net Worth of Larry Ellberger is at least $2.23 Milione dollars as of 25 August 2015. Larry Ellberger owns over 5,000 units of Celldex Therapeutics stock worth over $2,227,740 and over the last 15 years Larry sold CLDX stock worth over $0.
Larry has made over 7 trades of the Celldex Therapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently Larry bought 5,000 units of CLDX stock worth $70,000 on 25 August 2015.
The largest trade Larry's ever made was exercising 17,728 units of Celldex Therapeutics stock on 6 December 2013 worth over $144,660. On average, Larry trades about 2,929 units every 116 days since 2009. As of 25 August 2015 Larry still owns at least 53,500 units of Celldex Therapeutics stock.
You can see the complete history of Larry Ellberger stock trades at the bottom of the page.
Larry's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil e Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: